41st week of 2020 patent applcation highlights part 27 |
Patent application number | Title | Published |
20200317697 | CATALYST FOR POLYESTER POLYMERIZATION AND METHOD FOR PRODUCING POLYESTER RESIN - The present invention provides a catalyst for polyester polymerization capable of shortening production time of a polyester resin. | 2020-10-08 |
20200317698 | BETA-LACTAMASE INHIBITORS - Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections. | 2020-10-08 |
20200317699 | Chalcogenosilacyclopentanes - A new class of compounds known as chalcogenosilacyclopentanes is described. These compounds are five-membered ring structures containing a silicon-selenium or silicon-tellurium bond, as shown in Formulas (I) and (II). In these compounds, the substituents on the silicon and on the ring carbons may be hydrogen, alkyl, alkoxy, aromatic, or ether groups. The chalcogenosilacyclopentane compounds undergo ring-opening reactions with hydroxyl and other protic functionalities and may be used to prepare substrates that are amenable to thin film deposition techniques such as ALD and CVD. | 2020-10-08 |
20200317700 | SULFONYLDIAZOLES AND N-(FLUOROSULFONYL)AZOLES, AND METHODS OF MAKING THE SAME - The present disclosure provides methods for producing N-(fluorosulfonyl)azoles, sulfonyldiazoles, or related derivatives thereof; and the related products including N-(fluorosulfonyl)azoles, sulfonyldiazoles, and related derivatives thereof. For example, an N-(fluorosulfonyl)azole is obtained by reaction of sulfuryl fluoride with an azoles, an azole anion compound, a silylazole, or a combination thereof. Symmetric and asymmetric sulfonyldiazoles are obtained by further reaction of such an N-(fluorosulfonyl)azole with azoles, azole anion compounds, or silylazoles. A sulfonyldiazole can be also produced by reacting sulfuryl fluoride with an azole, a silylazole, or a combination thereof in one pot. | 2020-10-08 |
20200317701 | ORGANIC SILICON COMPOUND, AND ADDITIVE FOR RUBBER AND RUBBER COMPOSITION USING SAME - Provided is an organic silicon compound represented by formula (1), which when added to a rubber composition, can improve the wet traction performance of a cured product of the rubber composition, and significantly reduce a hysteresis loss of the cured product, and provides a rubber composition that can be used to implement a desired tire having high fuel efficiency. | 2020-10-08 |
20200317702 | Organoamino Functionalized Cyclic Oligosiloxanes For Deposition Of Silicon-Containing Films - Organoamino-functionalized cyclic oligosiloxanes have at least two silicon and two oxygen atoms as well as at least one organoamino group. Methods for depositing silicon and oxygen containing films are performed using the organoamino-functionalized cyclic oligosiloxanes. | 2020-10-08 |
20200317703 | MODIFIED LECITHIN FOR ASPHALT APPLICATIONS - Embodiments of the present invention provide a method, comprising obtaining a lecithin-containing material, in some aspects derived from a crude refining stream, comprising 20-80 wt % acetone insoluble matter, 1-30 wt % free fatty acid, and less than 10 wt % water, adding a fatty acid or carboxylic source to the lecithin-containing material to obtain a lecithin fatty acid blend or lecithin carboxylic acid blend and incorporating the blend into asphalt or oil field applications. | 2020-10-08 |
20200317704 | Organic Electronic Device Comprising an Organic Semiconductor Layer - The present invention relates to compounds comprising a TAE structure, for use as a layer material for electronic devices, and to an organic electronic device comprising the layer material, and a method of manufacturing the same. | 2020-10-08 |
20200317705 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS - The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use. | 2020-10-08 |
20200317706 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING THE COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THE COMPOUND, DISPLAY DEVICE, AND ILLUMINATION DEVICE - Provided is an iridium complex compound represented by formula (1) below. | 2020-10-08 |
20200317707 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME - Provided are an organometallic compound represented by Formula 1 and an organic light-emitting device including the same. The organic light-emitting device includes a first electrode; a second electrode facing the first electrode; an organic layer between the first electrode and the second electrode and including an emission layer; and at least one organometallic compound represented by Formula 1. | 2020-10-08 |
20200317708 | SUGAR-LINKED AMINO ACIDS FOR SOLID-PHASE PEPTIDE SYNTHESIS - The present disclosure relates to sugar-linked amino acids and processes for preparing the same. The sugar-linked amino acids may be used for solid-phase peptide synthesis. A sugar compound and an amino acid compound having a nucleophilic side chain are reacted in a heated halogenated solvent. The reaction is catalyst by a Lewis acid, such as InBr | 2020-10-08 |
20200317709 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 2020-10-08 |
20200317710 | Azithromycin Derivatives With Epithelial Barrier Enhancement Properties - The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention further provides use of the compounds as a medicament, in particular in the treatment or prophylaxis of a disease or condition that is caused by a defect in epithelial cells or tissue, or a disease or condition that benefits from enhancement or restoration of epithelial barrier function, for example diseases of the respiratory tract. | 2020-10-08 |
20200317711 | CYTARABINE PRODRUG NUCLEOSIDE CYCLIC PHOSPHATE COMPOUND BASED ON LIVERSPECIFIC DELIVERY AND USE - Disclosed are an anticancer prodrug nucleoside cyclic phosphate compound based on liver-specific delivery (LSD) technology and the use thereof, in particular, provided are a compound of formula (I) and an isomer, a pharmaceutically acceptable salt, a hydrate, a solvate and a corresponding pharmaceutical composition thereof, and the use of the compound alone or in combination with other anticancer drugs against cancer, especially in treating hepatic carcinoma (HCC). | 2020-10-08 |
20200317712 | LIVER SPECIFIC DELIVERY-BASED GEMCITABINE PRODRUG NUCLEOSIDE CYCLIC PHOSPHATE COMPOUND, AND APPLICATION THEREOF - Provided are a liver specific delivery (LSD)-based anticancer prodrug nucleoside cyclic phosphate compound and an application thereof, and in particular, a compound represented by formula (I) as well as isomers, pharmaceutically acceptable salts, hydrates, and solvates thereof, and corresponding pharmaceutical compositions. Also provided is an application of the compound alone or in combination with other anticancer drugs in anticancer area, particularly the treatment of hepatocellular carcinoma (HHC). | 2020-10-08 |
20200317713 | LIVER SPECIFIC DELIVERY-BASED ENTECAVIR PRODRUG, NUCLEOSIDE CYCLIC PHOSPHATE COMPOUND, AND APPLICATION THEREOF - Disclosed is a liver specific delivery (LSD)-based entecavir antiviral prodrug, i.e., a nucleoside cyclic phosphate compound, and the application thereof. Specifically, disclosed are a compound as represented by formula (I) and isomers, pharmaceutically acceptable salts, hydrates, and solvates of the compound, and a corresponding pharmaceutical composition. Also disclosed is the application of the compound of the present invention, used separately or used in combination with other antiviral drugs, against viruses, especially the application against hepatitis B virus (HBV). | 2020-10-08 |
20200317714 | CYCLIC PEROXIDES AS PRODRUGS FOR SELECTIVE DELIVERY OF AGENTS - Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a phannaceutically acceptable carrier. | 2020-10-08 |
20200317715 | PROCESS FOR PREPARATION OF OBETICHOLIC ACID - The invention of the present application relates to the process for the preparation of intermediates of obeticholic acid and their conversion to obeticholic acid. The process involves the conversion of compound of formula (VI) to compound of formula (VII) in presence of an organic base. | 2020-10-08 |
20200317716 | PREPARATION OF BILE ACIDS AND INTERMEDIATES THEREOF - Synthetic methods for preparing deoxycholic acid and intermediates thereof are provided. | 2020-10-08 |
20200317717 | PROCESS FOR PREPARATION OF SULFONYL CARBAMATE BILE ACID DERIVATIVES - The present invention relates to processes for preparing compounds of Formula (I) and Formula (II): | 2020-10-08 |
20200317718 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES - The invention relates to compounds of formula (II), | 2020-10-08 |
20200317719 | SAPONIN PURIFICATION - Saponin extracts containing at least 93% QS-21 main peak and 0.25-3% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects. | 2020-10-08 |
20200317720 | Production Method for Metal-Encapsulated Cage-Like Protein - The present invention provides a production method for a metal-encapsulated cage-like protein, comprising a step of introducing a metal element into a cage-like protein in the presence of a polysaccharide to produce a metal-encapsulated cage-like protein that encapsulates the metal element. | 2020-10-08 |
20200317721 | A PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE - A process for preparing a GLP-1 or GLP-2 peptide, said process comprising coupling in solution at least a first fragment and at least a second fragment, wherein the coupling comprises reacting the carboxy terminal amino acid of the first fragment with the amino terminal amino acid of the second fragment, and wherein the carboxy terminal amino acid of the first fragment is other than a Gly residue | 2020-10-08 |
20200317722 | SOLID PHASE SYNTHESIS OF NIR FLUORESCENT PROBE - The present invention discloses a solid-phase process for the preparation of a Near Infra-Red (NIR) fluorescent probe characterized by an aza-bicycloalkane based cyclic peptide labelled with a Cy5.5 dye moiety and used in the guided surgery of tumors and pathologic regions. | 2020-10-08 |
20200317723 | Bioconjugation of Polypeptides - Certain embodiments of the present invention relate to methods of forming and manipulating bioconjugates. Particularly, but not exclusively certain embodiments relate to methods of reversible carbon-carbon bond bioconjugation using aldol based chemical reactions at physiological conditions. | 2020-10-08 |
20200317724 | ENGINEERED O-GLYCOSYLATION IN RECOMBINANT POLYPEPTIDES AND USES THEREOF - The present invention relates to recombinant polypeptide therapeutics having an engineered O-linked amino acid (AA) glycosylation sequence (motif), which is covalently linked to O-glycan(s) (tag). Recombinant O-glycosylated polypeptides may be produced in mammalian cells to present natural or un-natural O-glycan structures through metabolic labelling. | 2020-10-08 |
20200317725 | Separation Method - The invention relates to a method of isolating an immunoglobulin, comprising the steps of:
| 2020-10-08 |
20200317726 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances - Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance. | 2020-10-08 |
20200317727 | PROTEIN PURIFICATION AND VIRUS INACTIVATION WITH ALKYL GLYCOSIDES - A process for purifying a recombinant protein comprising the steps of: i) providing a solution comprising the recombinant protein; ii) adding an alkyl glycoside to the solution; and iii) purifying the recombinant protein. The addition of the alkyl glycoside provides improved clearance of process-related impurities. The purified recombinant protein of the invention has low levels of host cell DNA, host cell protein and viral contamination. | 2020-10-08 |
20200317728 | CONTINUOUS PRODUCTION OF RECOMBINANT PROTEINS - The present disclosure relates to methods and systems for the continuous production of recombinant proteins. In particular embodiments, the disclosure relates to methods and systems using capture chromatography, post-capture chromatography, virus filtration, and ultrafiltration/diafiltration for the continuous production of recombinant proteins. | 2020-10-08 |
20200317729 | PEPTIDOMIMETIC PROTEASOME INHIBITORS - The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I′): where the substituents R, R | 2020-10-08 |
20200317730 | TARGETED NITROXIDE AGENTS - Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation. | 2020-10-08 |
20200317731 | Inhibitor of Apoptosis Protein (IAP) Antagonists - Provided herein are compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. | 2020-10-08 |
20200317732 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT - The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders. | 2020-10-08 |
20200317733 | FOXP3-BINDING PEPTIDES AND USES THEREOF - The present invention provides peptides of general formula (I) and salts thereof, wherein: R | 2020-10-08 |
20200317734 | AMYLOID-BETA-BINDING PEPTIDES AND THE USE THEREOF FOR THE TREATMENT AND DIAGNOSIS OF ALZHEIMER'S DISEASE - The invention relates to amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease. | 2020-10-08 |
20200317735 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS - β-Hairpin peptidomimetics of the general formula cyclo(-Xaa | 2020-10-08 |
20200317736 | STABILIZED POLYPEPTIDES AND USES THEREOF - The present invention features polypeptides which inhibit dimerization of small multidrug resistance transporters including a stabilized α-helix, and the use of such polypeptides in the treatment of bacterial infections. | 2020-10-08 |
20200317737 | Campylobacter Immunogenic Compositions and Uses Thereof - The present disclosure provides immunogenic compositions against | 2020-10-08 |
20200317738 | METHODS FOR INCREASING PROLIFERATION OF MAMMALIAN CELLS - The invention describes peptide, and proteins and fusion proteins comprising the peptides, that are capable of increasing the proliferation of cells, especially epithelial cells in the mammalian gastrointestinal tract. The peptides comprise the hydrophilic domain of the TadE subunit of the Tad pilus of Bifidobacterium, especially the pilus encoded by the Tad2003 gene cluster identified in Bifidobacterium breve UCC2003, and functional fragments of the hydrophilic domain. The invention informs new treatments for diseases and conditions that involve attenuated epithelial cell proliferation and growth, such as inflammatory conditions of the gastrointestinal tract and trauma of the skin including burns and other wounds. The invention also informs treatments of newborn babies to promote proliferation and growth of gut epithelial tissue by administration of agents comprising the peptide of the invention in the form of infant formula. | 2020-10-08 |
20200317739 | RECOMBINANT POLYPEPTIDES DERIVED FROM FBP1 AND FBP2 AND USES OF THE SAME - Disclosed herein are recombinant polypeptides derived from FBP1 and FBP2. Also disclosed herein are recombinant expression vectors and recombinant host cells for producing the aforesaid recombinant polypeptides. The recombinant polypeptides are proven to be useful and effective in producing a picornavirus with a type I internal ribosome entry site (IRES), so as to facilitate the preparation of a viral vaccine. | 2020-10-08 |
20200317740 | NOVEL PI3K GAMMA INHIBITOR PEPTIDE FOR TREATMENT OF RESPIRATORY SYSTEM DISEASES - Fusion peptide comprising: i) an amino acid sequence as defined in SEQ ID No.: 1 or a related homolog having at least 90% identity with SEQ ID No.: 1 and having the ability of the sequence SEQ ID No.: 1 to inhibit the kinase-independent function of PI3Kγ, and ii) a peptide having the ability to penetrate a cell. | 2020-10-08 |
20200317741 | COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH - The present invention relates to a composition for preventing the hair loss or promoting the hair growth, and according to the present invention, Wnt protein-derived peptides, polydeoxyribonucleotides or mixtures thereof increase the secretion of β-catenin, and increase the growth of keratinocytes, fibroblasts and dermal papilla cells which are hair constituent cells, by the cell activation and activation of signal transduction pathway for promoting the hair growth signaling system and to prevent the hair loss and promote the hair growth and therefore, Wnt protein-derived peptides, polydeoxyribonucleotides or mixtures thereof having the above effect can be used as a cosmetic composition, a pharmaceutical composition or a health food composition for preventing the hair loss or promoting the hair growth. | 2020-10-08 |
20200317742 | IMMUNOGENIC PEPTIDES AND THEIR USE IN IMMUNE DISORDERS - The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognised by CD4+ T cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides of the invention have been shown to be useful a medicine, more in particular for the prevention or treatment of immune disorders, more specifically of allergic disorders or autoimmune diseases. The present invention thus provides for the use of said peptides for the manufacture of a medicament for the prevention or treatment of an immune disorder and further provides for methods of treatment or preventing immune disorders by using said peptides. The present invention also provides for compositions comprising said peptides. | 2020-10-08 |
20200317743 | CHEMIGENETIC CALCIUM INDICATORS - A chemigenetic calcium indicator and a method of measuring calcium are provided. The chemigenetic calcium indicator includes a calcium-binding protein domain attached to a ligand binding protein domain. The method of measuring calcium includes administering a chemigenetic calcium indicator to a subject and determining changes in fluorescence, the chemigenetic calcium indicator including a ligand binding protein domain having a calcium-binding protein domain and a dye-ligand conjugate attached thereto. | 2020-10-08 |
20200317744 | De Novo Design of Potent and Selective Interleukin Mimetics - De novo designed polypeptides that bind to IL-2 receptor βγ | 2020-10-08 |
20200317745 | FRACTURE TARGETED BONE REGENERATION THROUGH PARATHYROID HORMONE RECEPTOR STIMULATION - Disclosed herein includes a drug delivery system comprising at least one peptide and a targeting ligand for bone fracture and/or for bone healing. Some embodiments include a peptide delivery system comprising at least an acidic, basic, hydrophilic, hydrophobic or neutral peptide linked to an acidic peptide or nonpeptidic polyanion for use in targeting the aforementioned attached peptide to a bone fracture surface. In some embodiments, a conjugated peptide expresses an anabolic function that acts through PTH receptor 1, and various formats of targeting ligands guide the drug to raw hydroxyapatite. This system offsets some side effects caused by free anabolic drug, such as high blood calcium concentration | 2020-10-08 |
20200317746 | TARGETED AND MODULAR EXOSOME LOADING SYSTEM - Disclosed are exosomes that include a packaging protein and a cargo RNA in which the packaging protein binds specifically to the cargo RNA. The packaging protein is a fusion protein that includes an RNA-binding domain and an exosome-targeting domain. The cargo RNA includes an RNA-motif that the RNA-binding domain of the fusion protein binds specifically such that the cargo RNA is packaged in the lumen of the exosomes. | 2020-10-08 |
20200317747 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF - The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide that exhibits reduced binding affinity to a cognate co-immunomodulatory polypeptide. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual. | 2020-10-08 |
20200317748 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-10-08 |
20200317749 | ALBUMIN VARIANTS FOR ENHANCED SERUM HALF-LIFE - The present disclosure relates to albumin variants, derivatives and analogs thereof. In particular, provided are albumin variants that bind with increased efficiency to FcRn, including albumin variants that bind with increased efficiency at low pH levels but inefficiently or not at all at neutral pH levels. The albumin variants, derivatives, and analogs have an increased serum half-life when compared to naturally-occurring albumins. | 2020-10-08 |
20200317750 | Molecular-Size of Elastin-Like Polypeptide Delivery System for Therapeutics Modulates Intrarenal Deposition and Bioavailability - A renal cortex targeting elastin-like polypeptide (ELP), a renal medulla and cortex targeting ELP, and a method of treating a renal disorder are provided. The renal cortex targeting ELP includes up to 95 repeat units having the sequence VPGXG (SEQ ID NO: 1), where X in each of the repeat units is any amino acid except proline. The renal medulla and cortex targeting ELP includes at least 95 repeat units of SEQ ID NO: 1, where X in each of the repeat units is any amino acid except proline. The method of treating a renal disorder includes administering an ELP and a therapeutic drug to a subject in need thereof, where the ELP includes up to 671 repeat units of SEQ ID NO: 1 and X in each of the repeat units is any amino acid except proline. | 2020-10-08 |
20200317751 | Antibodies, Variable Domains and Chains Tailored for Human Use - The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention. | 2020-10-08 |
20200317752 | Antibodies, Variable Domains and Chains Tailored for Human Use - The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention. | 2020-10-08 |
20200317753 | Humanized Antibodies Against Enterovirus 71 - The present invention provides humanized antibodies against Enterovirus 71 (EV71), a causative agent of hand, foot, and mouth disease (HFMD), as well as pharmaceutical compositions comprising these antibodies and methods of their use in the treatment, prophylaxis, and diagnosis of HFMD. These antibodies are suitable for use in human subjects with HFMD or those at risk of HFMD, for example as a result of exposure to infected individuals. | 2020-10-08 |
20200317754 | RSV-SPECIFIC BINDING MOLECULE - The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided. | 2020-10-08 |
20200317755 | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF - The invention relates to multispecific antibodies, and antigen binding fragments thereof, that specifically bind to distinct Zika virus epitopes and potently neutralize infection of ZIKV. The invention also relates to nucleic acids that encode such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in prophylaxis and treatment of ZIKV infection. | 2020-10-08 |
20200317756 | ANTIBODIES AND TEST DEVICES FOR THE DETECTION OF BACTERIA OF THE GENUS CAMPYLOBACTER - The present invention can be included in the field of diagnostics. The present invention provides hybridomas, antibodies and test devices for the detection of bacteria of the genus | 2020-10-08 |
20200317757 | COMBINATION THERAPIES USING ANTI-PSEUDOMONAS PSL AND PCRV BINDING MOLECULES - This disclosure relates to combination therapies comprising anti- | 2020-10-08 |
20200317758 | COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING STAPHYLOCOCCAL LEUKOTOXINS - The disclosure is directed to antibodies that bind to | 2020-10-08 |
20200317759 | IMMUNOGENIC COMPOSITIONS COMPRISING STAPHYLOCOCCUS AUREUS LEUKOCIDIN LUKA AND LUKB DERIVED POLYPEPTIDES - The present disclosure provides immunogenic compositions useful in prevention and treatment of | 2020-10-08 |
20200317760 | Motif-Specific and Context-Independent Antibodies That Specifically Bind to a Sumoylated Lysine-Containing Residue - There is provided a motif-specific, context-independent antibody that specifically binds a recurring, modified motif consisting of (i) at least one sumoylated lysine residue, and (ii) one or more degenerate amino acids bound by a peptide bond to said sumoylated lysine residue, said antibody specifically binding said motif in a plurality of non-homologous peptides or proteins within an organism in which it recurs. Also provided is a motif-specific, context-independent antibody that specifically binds a recurring, modified motif consisting of (i) a C-terminal aspartic acid residue, and (ii) one or more degenerate amino acids bound by a peptide bond to said C-terminal aspartic acid residue, said antibody specifically binding said motif in a plurality of non-homologous peptides or proteins within an organism in which it recurs. | 2020-10-08 |
20200317761 | MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2 - Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies. | 2020-10-08 |
20200317762 | COMPLEMENT FACTOR Bb ANTIBODIES - The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies. | 2020-10-08 |
20200317763 | ANTIBODIES RECOGNIZING ALPHA-SYNUCLEIN - The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer' s disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA). | 2020-10-08 |
20200317764 | MODIFIED MRNA FOR MULTICELL TRANSFORMATION - Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro. Codon modification of the mRNA can optimize expression of an immunogenic polypeptide in cancer cells. | 2020-10-08 |
20200317765 | ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF - The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same. | 2020-10-08 |
20200317766 | ANTIBODIES TO CENTRIN-1, METHODS OF MAKING, AND USES THEREOF - Provided herein are antibodies that specifically bind Centrin-1 and methods of making the same, for use the treatment, prevention, detection, imaging, and diagnosis of cancers including pancreatic and prostate cancer. | 2020-10-08 |
20200317767 | GROWTH DIFFERENTIATION FACTOR (GDF) FOR TREATMENT OF DIASTOLIC HEART FAILURE - The methods and uses described herein relate to the treatment of age-related conditions, e.g. by administering an agent that inhibits the interaction of GDF11 and follistatin. In some embodiments, the agent can bind to an epitope of GDF11 as described herein. | 2020-10-08 |
20200317768 | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE - The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation. | 2020-10-08 |
20200317769 | POLYPEPTIDES - There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification. | 2020-10-08 |
20200317770 | ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL) - Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy. | 2020-10-08 |
20200317771 | Method of Administration of an Anti-IFN-alpha/-omega Antibody - Methods for administration of an anti-IFN-α/-ω antibody by subcutaneous or intravenous administration in a clinically proven safe amount are provided. Also provided are methods for clinically proven safe treatment of IFN-I mediated diseases, such as systemic lupus erythematosus (SLE), by subcutaneous or intravenous administration of an anti-IFN-α/-ω antibody. | 2020-10-08 |
20200317772 | ANTI-ACTH ANTIBODIES AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the V | 2020-10-08 |
20200317773 | NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 2020-10-08 |
20200317774 | ANTI-HUMAN CD19 ANTIBODIES WITH HIGH AFFINITY - The present invention relates to antibodies against human CD19 (anti-human CD19 antibodies), methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same. | 2020-10-08 |
20200317775 | SP35 Antibodies And Uses Thereof - Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody. | 2020-10-08 |
20200317776 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof. | 2020-10-08 |
20200317777 | ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF - The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of chimeric antigen receptors (CARs) and engineered immunoresponsive cells comprising the same. The engineered immunoresponsive cells comprising the novel CARs are antigen-directed and have extended persistence without compromising function. | 2020-10-08 |
20200317778 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES - Provided herein are compositions, methods, kits and systems for treating cells, tissues and subjects to alter age-related biology (e.g., to study or to treat age-related diseases and conditions). In particular, provided herein are compositions, methods, and uses for inhibition or modification of sialic acid or its cognate receptor to restore phagocytosis in aged cells. | 2020-10-08 |
20200317779 | ANTI-CD3 ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME - The present invention relates to an anti-CD3 antibody and a pharmaceutical composition for cancer treatment comprising same. The antibody according to the present invention has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment. | 2020-10-08 |
20200317780 | METHODS FOR ENHANCING TCRab+ CELL DEPLETION - Provided herein are improved methods for robust TCR+ cell depletion and production of populations of TCR− cells, which can be beneficial to minimize the GvHD risk in patients receiving allogeneic CAR T cell therapy. Provided herein are methods that increase the efficiency of depleting TCR+ cells from a population of cells in order to significantly reduce any residual levels of TCR+ cells present in cell populations in which expression of endogenous TCR has been reduced or eliminated. Associated kits and cell populations are also provided. | 2020-10-08 |
20200317781 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | 2020-10-08 |
20200317782 | PROTEIN-BASED T-CELL RECEPTOR KNOCKDOWN - The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies. | 2020-10-08 |
20200317783 | BISPECIFIC ANTIBODY - A prophylactic, symptom progress-suppressive, recurrence-suppressive and/or therapeutic agent for autoimmune disease or graft-versus-host disease, comprising a PD-1/CD19 bispecific antibody or antibody fragment thereof having a first arm capable of specifically binding to PD-1 and a second arm capable of specifically binding to CD19, as an active ingredient. The PD-1/CD19 bispecific antibody exhibits suppressive effect on proliferation of activated B cells and suppressive effect on production of immunoglobulin, and also has an effect of suppressing production of cytokine from memory T cells. | 2020-10-08 |
20200317784 | METHODS AND COMPOSITIONS FOR TREATING CANCER BY MODIFYING MULTIPLE ARMS OF THE IMMUNE SYSTEM - Provided herein are combination methods and compositions for cancer therapies. The combinations modify multiple arms of the immune system, including an innate immunity modifier, an immune checkpoint inhibitor and a T-cell stimulator, to treat cancer. | 2020-10-08 |
20200317785 | PD1 BINDING AGENTS - Provided herein are antibody molecules that bind specifically to Programmed cell death 1 (PD1) and related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules. | 2020-10-08 |
20200317786 | ANTIBODIES TO ICOS - Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Combinations of anti-ICOS antibodies and other drugs for immunooncology. | 2020-10-08 |
20200317787 | FUSION PROTEIN DIMER USING ANTIBODY FC REGION AS BACKBONE AND USE THEREOF - Provided is a fusion protein dimer using an antibody Fc region as the backbone, comprising a first and a second polypeptide chain. The first polypeptide chain comprises a first antibody Fc region and one or more single-domain antibodies fused to the first antibody Fc region. The second polypeptide chain comprises a second antibody Fc region and one or more single domain antibodies fused to the second antibody Fc region. The first polypeptide chain and/or the second polypeptide chain further comprise a cytokine fused to the Fc region of the respective antibody. Further provided is use of the fusion protein dimer in preparing an immunotherapeutic drug for treating tumors. The Fc fusion protein heterodimer not only increases the activity of a single domain antibody, but also significantly improves the biological activity of a cytokine. Further, by means of the targeting specificity of the antibody, the targeted transport of the cytokine is effectively enhanced, and cytotoxicity is attenuated, thereby obtaining better anti-tumor potential. | 2020-10-08 |
20200317788 | SEMAPHORIN-4D ANTAGONISTS FOR USE IN CANCER THERAPY - The disclosure relates to methods for treating cancer comprising determining certain patient biomarker levels prior to treatment. | 2020-10-08 |
20200317789 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF - Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided. | 2020-10-08 |
20200317790 | ANTI-HLA-DQ2.5 ANTIBODY - The antibodies of the present invention have specific binding activity to HLA-DQ2.5 and may have binding activity to HLA-DQ2.2 and/or HLA-DQ7.5, but substantially no binding activity to HLA-DQ8, HLA-DQ5.1, HLA-DQ6.3, HLA-DQ7.3, HLA-DR, HLA-DP, or a complex of the invariant chain (CD74) and HLA-DQ2.5. The antibodies bind to HLA-DQ2.5 in the presence of a gluten peptide such as gliadin, i.e., bind to HLA-DQ2.5 forming a complex with the gluten peptide. The antibodies have neutralizing activity against the binding between HLA-DQ2.5 and TCR, and thus block the interaction between HLA-DQ2.5 and an HLA-DQ2.5-restricted CD4+ T cell. The antibodies do not undergo rapid internalization mediated by the invariant chain. | 2020-10-08 |
20200317791 | Anti-HLA-C Antibodies and Uses Thereof - Anti-HLA-C6 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as autoimmune diseases. | 2020-10-08 |
20200317792 | ANTIBODIES AND METHODS OF MAKING SAME - Provided are variants of a chimeric anti-EGFR antibody. In various embodiments, the variants exhibit substantially improved thermostabilities and/or substantially higher levels of humanness, while retaining binding affinity near the parental level. The consistently high quality of the turnkey CoDAH designs, over a whole panel of variants, suggests that a computationally-directed approach encapsulates key determinants of antibody structure and function. | 2020-10-08 |
20200317793 | ANTI-PAD4 AUTOANTIBODIES AS CLINICAL RESPONSE BIOMARKERS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS - The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods. | 2020-10-08 |
20200317794 | ANTI-CD154 ANTIBODIES AND METHODS OF USING THEM - The present invention relates to antagonistic antibodies specifically binding CD154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing. | 2020-10-08 |
20200317795 | TRANSTHYRETIN IMMUNOGLOBULIN FUSIONS - The present invention relates to transthyretin (TTR) fusions useful in the dimerization and tetramerization of antibodies and antibody fragments, such as Fabs. The TTR fusions proteins described herein are particularly useful in increasing antibody avidity and in enhancing antigen clustering. Methods for treating diseases using the fusion proteins of the present invention are described herein. | 2020-10-08 |
20200317796 | ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity. | 2020-10-08 |